Legal Proceedings	6 Months Ended
Jun. 28, 2025
Legal Proceedings [Abstract]
Legal Proceedings	Note 11 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one- hundred ( 100 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. We have reached a settlement agreement in principle with hospital plaintiffs in sixteen cases, including the case filed by Florida Health Sciences Center (and other hospitals) in Florida state court, which was scheduled for trial in September 2025, for an immaterial amount. That trial has been stayed as to Henry Schein pending finalization of the settlement agreement. We have also agreed to settle fifty-nine cases filed by Virginia municipalities for an immaterial amount. Finalization of the settlement agreement in those cases is pending. Of Henry Schein’s 2024 net sales of approximately $ 12.7 billion, sales of opioids represented less than four -tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of June 28, 2025, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Henry Schein, Inc. has been named as a defendant in multiple opioid

related lawsuits (currently less than one-

hundred (

100

); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of

those

cases).

Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false

advertising campaign to expand the market for such drugs and their own

market share and that the entities in the

supply chain (including Henry Schein, Inc. and its subsidiaries) reaped

financial rewards by refusing or otherwise

failing to monitor appropriately and restrict the improper distribution of those

drugs.

These actions consist of some

that have been consolidated within the MultiDistrict Litigation (“MDL”)

proceeding In Re National Prescription

Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently

stayed, and others which remain

pending in state courts and are proceeding independently and outside of

the MDL.

We have reached a settlement

agreement in principle with hospital plaintiffs in

sixteen

cases, including the case filed by Florida Health Sciences

Center (and other hospitals) in Florida state court, which was scheduled

for trial in September 2025, for an

immaterial amount.

That trial has been stayed as to Henry Schein pending finalization

of the settlement agreement.

We have also agreed to settle

fifty-nine

cases filed by Virginia municipalities for an immaterial amount.

Finalization of the settlement agreement in those cases is pending.

Of Henry Schein’s 2024 net sales of

approximately $

12.7

billion, sales of opioids represented less than

four

-tenths of 1 percent.

Opioids represent a

negligible part of our business.

We intend to defend ourselves vigorously against these actions.

From time to time, we may become a party to other legal proceedings,

including, without limitation, product

liability claims, employment matters, commercial disputes, governmental

inquiries and investigations (which may

in some cases involve our entering into settlement arrangements or consent

decrees), and other matters arising out

of the ordinary course of our business.

While the results of any legal proceeding cannot be predicted with certainty,

in our opinion none of these other pending matters are currently

anticipated to have a material adverse effect on our

consolidated financial position, liquidity or results of operations.

As of June 28, 2025, we had accrued our best estimate of potential

losses relating to claims that were probable to

result in liability and for which we were able to reasonably estimate a

loss.

This accrued amount, as well as related

expenses, was not material to our financial position, results of operations

or cash flows.

Our method for

determining estimated losses considers currently available

facts, presently enacted laws and regulations and other

factors, including probable recoveries from third parties.